| Ytd | -42.25% | |
| 1y | -8.50% |
| Open | 9.08 | Prev Close | 9.18 | Low | 9.07 | High | 9.59 | Mkt Cap | 775.03M |
| Vol | 908.08K | Avg Vol | 1.33M | EPS | -1.47 | P/E | -6.52 | Forward P/E | 7.60 |
| Beta | 0.61 | Short Ratio | 9.36 | Inst. Own | 83.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 10.45 | 200-d Avg | 12.45 | 1yr Est | 23.70 |
PHAT News
Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in bel
NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses aft
/PRNewswire/ -- Investors in Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) were told the Company's fu
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales fo
Phathom Pharmaceuticals NASDAQ: PHAT reported second-quarter 2026 revenue growth of 88% year over ye
Phathom Pharmaceuticals, Inc. (PHAT) reported break-even quarterly earnings per share versus the Zac
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host con
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Za
FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., A
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has received a consensus recommendati
FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
On Friday, 469 companies hit new 52-week lows.